{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-016487","form_type":"8-K","ticker":"DMAC","cik":"0001401040","company_name":"DiaMedica Therapeutics Inc.","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.170510+00:00","generated_at":"2026-05-21T14:16:37.659662+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"DiaMedica reports Q1 net loss $7.7M; preeclampsia Phase 2 topline data expected June-July 2025","bullets":["Net loss $7.7M ($0.18/sh) vs $5.2M ($0.14) in Q1 2024; R&D expense rose to $5.7M on trial expansion.","Cash $37.3M as of Mar 31, 2025 (down from $44.1M Dec 2024); runway into Q3 2026.","Phase 2 preeclampsia Part 1A topline results expected between 2H June and 1H July 2025; KOL event May 28.","ReMEDy2 stroke trial enrollment progressing; interim analysis on first 200 patients expected H1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-016487","json":"https://secwatch.observer/filing/0001437749-25-016487.json","markdown":"https://secwatch.observer/filing/0001437749-25-016487.md","text":"https://secwatch.observer/filing/0001437749-25-016487.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401040/000143774925016487/0001437749-25-016487-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401040/000143774925016487/dmtp20250512_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T14:16:37.659662+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}